04:59 PM EST, 03/06/2026 (MT Newswires) -- Incyte ( INCY ) said late Friday the European Commission approved the Zynyz regimen to treat adults with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal.

This commission's decision is based on data from a phase 3 trial, the company said.

The commission's approval follows the positive opinion received in January from the European Medicines Agency's Committee for Medicinal Products for Human Use, the company said.